Trial abstracts in the registry — page 6
700 documents of type trial abstract.
Documents
-
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low11 May 2024 -
Randomised crossover, phase 1 study of Liraglutide in prediabetes and obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low11 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Orforglipron in obesity randomising 272 participants over 36 weeks. Primary result: Mean change up to…
Moderate09 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Glutathione in cognition over as stated in the parent protocol. The Institute holds no reported primary…
Very low09 May 2024 -
Randomised, double-blind, placebo-controlled, phase 1 study of Thymosin beta-4 in cardiovascular over as stated in the parent protocol. The Institute holds no reported…
Very low08 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low07 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tirzepatide in mash randomising 190 participants over 52 weeks. Primary result: Resolution in 44 % to 62 %…
Low06 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low04 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity and type 2 diabetes randomising 938 participants over 72 weeks. Primary result…
High02 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of GHK-Cu in wound healing over 12 weeks. Primary result: Directionally consistent with the companion study…
Low02 May 2024 -
Single-arm open-label, phase 3 study of Tirzepatide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low02 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no…
Very low02 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low01 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low28 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Pramlintide in obesity randomising 411 participants over 16 weeks. Primary result: A weight reduction of…
Low27 Apr 2024 -
Randomised crossover study of DSIP in sleep over not recorded. Primary result: Historical crossover studies in small samples reported inconsistent effects on sleep…
26 Apr 2024 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low26 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low25 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low25 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low22 Apr 2024 -
Single-arm open-label, phase 3 study of Exenatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low20 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Apr 2024 -
Randomised, double-blind, placebo-controlled study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low16 Apr 2024 -
Randomised crossover, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low15 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Liraglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Liraglutide in mash randomising 52 participants over 48 weeks. Primary result: Resolution in 39 % versus 9…
Low12 Apr 2024 -
Observational, phase 2 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low11 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low10 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The Institute holds no reported…
Very low09 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low07 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Pramlintide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Exenatide in cardiovascular randomising 91 participants over 6 months. Primary result: No significant…
Moderate04 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low04 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low04 Apr 2024 -
Randomised crossover, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low02 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low01 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low31 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low30 Mar 2024
page 6 of 18